Pfizer Inc. (PFE)
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day.
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer shares fall after it forecasts 2026 revenue below estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.
Here's why Pfizer is revising its revenue forecasts
The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings
Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a share.
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharma's oral drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk's blockbuster weight loss injection Wegovy, but the pill is still in early-stage development.
